| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rosalie Vozzo, Ben Baker, Gary A Wittert, Judith M Wishart, Howard Morris, Michael Horowitz, Ian Chapma. Glycemic, hormone, and appetite responses to monosaccharide ingestion in patients with type 2 diabetes. Metabolism: clinical and experimental. vol 51. issue 8. 2002-08-15. PMID:12145765. |
to investigate the relative effects of fructose and glucose on blood glucose, plasma insulin and incretin (glucagon-like peptide-1 [glp-1] and gastric inhibitory peptide [gip]) concentrations, and acute food intake, 10 (6 men, 4 women) patients with diet-controlled type 2 diabetes (diabetic) (44 to 71 years) and 10 age and body mass index (bmi)-matched (6 men, 4 women) nondiabetic, control subjects with varying degrees of glucose tolerance (nondiabetic), were studied on 3 days. |
2002-08-15 |
2023-08-12 |
human |
| Elizabeth J Abraham, Colin A Leech, Julia C Lin, Henryk Zulewski, Joel F Habene. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. vol 143. issue 8. 2002-08-13. PMID:12130581. |
recently glp-1 was shown to stimulate the growth and differentiation (neogenesis) of beta-cells and appears to do so by inducing the expression of the homeodomain protein idx-1 (islet duodenum homeobox-1; also known as pdx-1, pancreatic and duodenal homeobox gene; and as ipf-1, insulin promoter factor), which is required for pancreas development and the expression of beta-cell-specific genes. |
2002-08-13 |
2023-08-12 |
human |
| M A Luque, N González, L Márquez, A Acitores, A Redondo, M Morales, I Valverde, M L Villanueva-Peñacarrill. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. The Journal of endocrinology. vol 173. issue 3. 2002-08-09. PMID:12065236. |
in muscle strips, glp-1, like insulin, stimulated glycogen synthesis, glycogen synthase a activity, and glucose oxidation and utilization, and inhibited glycogen phosphorylase a activity, all of this at physiological concentrations of the peptide. |
2002-08-09 |
2023-08-12 |
human |
| M A Luque, N González, L Márquez, A Acitores, A Redondo, M Morales, I Valverde, M L Villanueva-Peñacarrill. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. The Journal of endocrinology. vol 173. issue 3. 2002-08-09. PMID:12065236. |
in cultured myotubes, glp-1 exerted, from 10(-13) mol/l, a dose-related increase of the d-[u-(14)c]glucose incorporation into glycogen, with the same potency as insulin, together with an activation of glycogen synthase a; the effect of 10(-11) mol/l glp-1 on both parameters was additive to that induced by the equimolar amount of insulin. |
2002-08-09 |
2023-08-12 |
human |
| M A Luque, N González, L Márquez, A Acitores, A Redondo, M Morales, I Valverde, M L Villanueva-Peñacarrill. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. The Journal of endocrinology. vol 173. issue 3. 2002-08-09. PMID:12065236. |
glp-1, exendin-4, ex-9 and insulin all induced the prompt hydrolysis of glycosylphosphatidylinositols (gpis). |
2002-08-09 |
2023-08-12 |
human |
| Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki, Takashi Inoue, Isao Tanak. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life sciences. vol 71. issue 2. 2002-07-30. PMID:12031691. |
this enzyme degrades glucagon-like peptide-1 (glp-1), which induces glucose-dependent insulin secretion. |
2002-07-30 |
2023-08-12 |
rat |
| Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki, Takashi Inoue, Isao Tanak. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life sciences. vol 71. issue 2. 2002-07-30. PMID:12031691. |
glucose tolerance of f344/ducrj rats is improved as a result of enhanced insulin release induced by high levels of plasma glp-1. |
2002-07-30 |
2023-08-12 |
rat |
| Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki, Takashi Inoue, Isao Tanak. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life sciences. vol 71. issue 2. 2002-07-30. PMID:12031691. |
these observations suggest that dppiv deficiency results in improved glucose tolerance and ameliorated insulin resistance owing to enhanced insulin release and inhibition of food intake as a result of high active glp-1 levels. |
2002-07-30 |
2023-08-12 |
rat |
| S Y Chae, S W Kim, Y H Ba. Bioactive polymers for biohybrid artificial pancreas. Journal of drug targeting. vol 9. issue 6. 2002-07-24. PMID:11822819. |
glucagon-like peptide-1 (glp-1, 7-37) is known to have a strong stimulatory effect on insulin secretion, particularly at high glucose concentrations. |
2002-07-24 |
2023-08-12 |
Not clear |
| S Y Chae, S W Kim, Y H Ba. Bioactive polymers for biohybrid artificial pancreas. Journal of drug targeting. vol 9. issue 6. 2002-07-24. PMID:11822819. |
when zinc-crystallized glp-1 was entrapped along with islets in a hollow fiber macrocapsule device, insulin secretion was enhanced at a high glucose concentration (300 mg/dl) with a >85% increase in insulin secretion after an induction period. |
2002-07-24 |
2023-08-12 |
Not clear |
| Hongxiang Hui, Loredana Farilla, Patricia Merkel, Riccardo Perfett. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European journal of endocrinology. vol 146. issue 6. 2002-07-24. PMID:12039708. |
the incretin hormone glucagon-like peptide-1 (glp-1) is capable of ameliorating glucose-dependent insulin secretion in subjects with diabetes. |
2002-07-24 |
2023-08-12 |
human |
| Hongxiang Hui, Loredana Farilla, Patricia Merkel, Riccardo Perfett. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European journal of endocrinology. vol 146. issue 6. 2002-07-24. PMID:12039708. |
this was reflected in the higher insulin levels attained in the glp-1-treated animals (1999+/-163 vs 1250+/-51 pmol/l, glp-1 vs saline respectively, p<0.01). |
2002-07-24 |
2023-08-12 |
human |
| Hongxiang Hui, Loredana Farilla, Patricia Merkel, Riccardo Perfett. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European journal of endocrinology. vol 146. issue 6. 2002-07-24. PMID:12039708. |
indeed, the best insulin secretory response was observed approximately 1 week after discontinuation of the glp-1 infusion, and lasted up to 3 weeks from the early exposure to glp-1. |
2002-07-24 |
2023-08-12 |
human |
| Hiroshi Yamamoto, Charlotte E Lee, Jacob N Marcus, Todd D Williams, J Michael Overton, Marisol E Lopez, Anthony N Hollenberg, Laurie Baggio, Clifford B Saper, Daniel J Drucker, Joel K Elmquis. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. The Journal of clinical investigation. vol 110. issue 1. 2002-07-24. PMID:12093887. |
glucagon-like peptide-1 (glp-1) released from the gut functions as an incretin that stimulates insulin secretion. |
2002-07-24 |
2023-08-12 |
rat |
| A J Scheen, M R Letiexhe, I Geronooz, N Paquot, B Jandrai. [Postprandial hyperglycemia. II. Pharmacological approaches]. Revue medicale de Liege. vol 57. issue 4. 2002-07-16. PMID:12073790. |
glp-1 or insulin while other glucagon antagonists are currently in development. |
2002-07-16 |
2023-08-12 |
Not clear |
| Mary Jeanne DeLeon, Vikram Chandurkar, Stewart G Albert, Arshag D Mooradia. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes research and clinical practice. vol 56. issue 2. 2002-06-06. PMID:11891017. |
the anti-hyperglycemic effect of alpha-glucosidase inhibitors (agi) is partly attributed to their ability to stimulate the secretion of glucagon-like peptide-1 (glp-1), a gut hormone with insulin stimulating capability. |
2002-06-06 |
2023-08-12 |
human |
| Mary Jeanne DeLeon, Vikram Chandurkar, Stewart G Albert, Arshag D Mooradia. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes research and clinical practice. vol 56. issue 2. 2002-06-06. PMID:11891017. |
the serum glucose, insulin, triglycerides and glp-1 levels were measured at baseline and at 1 and 2 h postprandially. |
2002-06-06 |
2023-08-12 |
human |
| Mary Jeanne DeLeon, Vikram Chandurkar, Stewart G Albert, Arshag D Mooradia. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes research and clinical practice. vol 56. issue 2. 2002-06-06. PMID:11891017. |
there were no significant correlations between serum glp-1 and serum glucose or insulin levels. |
2002-06-06 |
2023-08-12 |
human |
| J Cancelas, M L Villanueva-Peñacarrillo, I Valverde, W J Malaiss. Suppression by exendin(9-39)amide of glucagon-like peptide-1 insulinotropic action in rats infused with dimethyl ester of succinic acid. Endocrine. vol 15. issue 3. 2002-05-20. PMID:11762700. |
in the present study, a primed constant infusion of sad (0.5 micromol followed by 0.25 micromol/min both per g of body wt) was found to increase plasma insulin concentration in fed anesthetized rats, to potentiate the b-cell secretory response to glp-1 (0.5 pmol/g of body wt), and to unmask the hypoglycemic potential of the gastrointestinal hormone. |
2002-05-20 |
2023-08-12 |
rat |
| J Cancelas, M L Villanueva-Peñacarrillo, I Valverde, W J Malaiss. Suppression by exendin(9-39)amide of glucagon-like peptide-1 insulinotropic action in rats infused with dimethyl ester of succinic acid. Endocrine. vol 15. issue 3. 2002-05-20. PMID:11762700. |
in the sad-infused rats, the infusion of exendin(9-39)amide (5.0 pmol/min per g of body wt), 1 min before and 3 min after glp-1 injection, decreased plasma insulin concentration before glp-1 injection, suppressed the b-cell secretory response to glp-1, and both delayed and minimized its hypoglycemic action. |
2002-05-20 |
2023-08-12 |
rat |